169614-87-3

Upstream product

• 6898-86-8 3-methyl-4-phenylfuroxan 
• 1370705-54-6 3-(azidomethyl)-4-phenyl-1,2,5-oxadiazole-2-oxide 
• 104-54-1 3-Phenylpropenol 
• 169614-78-2 3-(bromomethyl)-2-oxido-4-phenyl-1,2,5-oxadiazole 
• 217966-10-4 3-chloromethyl-4-phenyl-1,2,5-oxadiazole N²-oxide 
• 135733-30-1 3-(hydroxymethyl)-4-phenylfuroxan 
• 169614-84-0 2-(2-Oxy-4-phenyl-furazan-3-ylmethyl)-isoindole-1,3-dione 

Downstream Products

• 1370705-82-0 (S)-3-((4-methyl-2-(phenylsulfonamido)pentanamido)methyl)-4-phenyl-1,2,5-oxadiazole-2-oxide 
• 1370705-88-6 (R)-4-methyl-N-((4-phenyl-1,2,5-oxadiazol-3-yl)methyl)-2-(phenylsulfonamido)pentanamide 

Relevant academic research and scientific papers

Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists

The P2X7 receptor is a promising target for the treatment of various diseases due to its significant role in inflammation and immune cell signaling. This work describes the design, synthesis, and in vitro evaluation of a series of novel derivatives bearing diverse scaffolds as potent P2X7 antagonists. Our approach was based on structural modifications of reported (adamantan-1-yl)methylbenzamides able to inhibit the receptor activation. The adamantane moieties and the amide bond were replaced, and the replacements were evaluated by a ligand-based pharmacophore model. The antagonistic potency of the synthesized analogues was assessed by two-electrode voltage clamp experiments, using Xenopus laevis oocytes that express the human P2X7 receptor. SAR studies suggested that the replacement of the adamantane ring by an aryl-cyclohexyl moiety afforded the most potent antagonists against the activation of the P2X7 cation channel, with analogue 2-chloro-N-[1-(3-(nitrooxymethyl)phenyl)cyclohexyl)methyl]benzamide (56) exhibiting the best potency with an IC50 value of 0.39 μΜ.

Furoxans (1,2,5-Oxadiazole- N -oxides) as novel no mimetic neuroprotective and procognitive agents

Furoxans (1,2,5-oxadiazole-N-oxides) are thiol-bioactivated NO-mimetics that have not hitherto been studied in the CNS. Incorporation of varied substituents adjacent to the furoxan ring system led to modulation of reactivity toward bioactivation, studied

Synthesis and biological evaluation of 1,2,5-oxadiazole N-oxide derivatives as hypoxia-selective cytotoxins

Synthesis and biological evaluation of new 1,2,5-oxadiazole N-oxide derivatives with potential cytotoxic effects are described. From the series of compounds tested, compounds 2 and 6 proved to be very active, although non-selective.

Unsymmetrically Substituted Furoxans. Part 15. Bromination of Dimethylfuroxan and Related Compounds with NBS

Treatment of the dimethylfuroxan 1 and of the two methylphenylfuroxan isomers 4, 5 with N-bromosuccinimide (NBS) shows that the methyl group linked at the 3-position of the furoxan ring is selectively brominated.The same reaction run with the 3-methyl-4-nitrofuroxan 8 and with the 4-ethoxy-3-methylfuroxan 9 bears evidence that the reactivity of the 3-methyl group is dependent on the nature of the substituent at the 4-position. 3-Bromomethylfuroxan derivatives easily undergo nucleophilic substitutions to afford a variety of unsymmetrically substituted furoxans.